远程技术与1型糖尿病管理
1型糖尿病需要强化自我管理以预防急性和长期并发症。过去二十年技术显著进步,但近端技术(胰岛素泵、持续葡萄糖监测、闭环系统)已被频繁综述,而远程技术(远程医疗、移动健康应用、游戏化支持、社交平台、患者门户)受关注较少。本综述汇总实证文献,评估现有远程技术改善1型糖尿病管理的有效性,并讨论隐私、伦理、监管、全球采用、知识缺口及未来方向。
要点
- 远程技术包括远程医疗、移动健康应用、游戏化支持、社交平台和患者门户等异质性系统。
- 本综述汇总实证文献,提供远程技术改善1型糖尿病管理有效性的当前信息。
- 综述还讨论隐私、伦理、监管、全球采用、知识缺口及未来方向建议。
核心结论
- 本综述汇总实证文献,提供远程技术改善1型糖尿病管理有效性的当前信息。
研究设计与样本
- 本文为综述,汇总实证文献以提供远程技术改善1型糖尿病管理有效性的当前信息。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Type 1 diabetes requires intensive self-management to avoid acute and long-term health complications. In the past two decades, substantial advances in technology have enabled more effective and convenient self-management of type 1 diabetes. Although proximal technologies (eg, insulin pumps, continuous glucose monitors, closed-loop and artificial pancreas systems) have been the subject of frequent systematic and narrative reviews, distal technologies have received scant attention. Distal technologies refer to electronic systems designed to provide a service remotely and include heterogeneous systems such as telehealth, mobile health applications, game-based support, social platforms, and patient portals. In this Review, we summarise the empirical literature to provide current information about the effectiveness of available distal technologies to improve type 1 diabetes management. We also discuss privacy, ethics, and regulatory considerations, issues of global adoption, knowledge gaps in distal technology, and recommendations for future directions.
引用
- Duke DC, Barry S, Wagner DV, et al. Distal technologies and type 1 diabetes management. Lancet Diabetes Endocrinol. 2017. PMID: 28867311. doi:10.1016/S2213-8587(17)30260-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。